Kenvue Inc. (NYSE:KVUE) Shares Sold by Commerce Bank

Commerce Bank reduced its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 10.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 143,023 shares of the company's stock after selling 16,608 shares during the quarter. Commerce Bank's holdings in Kenvue were worth $3,054,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Grove Bank & Trust raised its stake in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the 4th quarter worth about $29,000. SRS Capital Advisors Inc. boosted its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC boosted its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after acquiring an additional 1,441 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of NYSE KVUE traded up $0.28 during mid-day trading on Friday, hitting $23.03. The company had a trading volume of 22,247,462 shares, compared to its average volume of 17,101,620. The stock has a market cap of $44.19 billion, a price-to-earnings ratio of 43.45, a PEG ratio of 2.62 and a beta of 1.02. The firm's 50 day simple moving average is $23.01 and its two-hundred day simple moving average is $22.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date is Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is 154.72%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on KVUE shares. Barclays decreased their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Monday, April 14th. UBS Group dropped their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Citigroup upped their price objective on shares of Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a research report on Monday, April 14th. Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.